Key facts
- It has raised $136.9M across 1 recorded rounds; the latest was Early Stage VC (Series A1) ($48.5M) in Jul 2024.
- Notable investors include RA Capital Management, F-Prime Capital, OrbiMed, Labcorp Venture Fund, Deerfield Management — 7 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Adela
Funding rounds
1 roundsAbout Adela
Operator of a minimal residual disease monitoring platform intended to help in early cancer detection. The company offers a product that can detect tumors and classify them using plasma cell-free DNA methylomes, enabling doctors in cancer detection and prenatal diagnostics, cardiology, and monitoring of immune responses.
- Industry
- Diagnostic Equipment
- Sector
- Healthcare
- HQ
- Foster City, CA, United States
- Founded
- 2020
- Employees
- 62
- Website
- adelabio.com/
- Ownership
- Privately Held (backing)
Adela doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Adela shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Adela in its N-PORT filings yet. We sweep new filings monthly.